- PR Newswire•11 hours ago
CUPERTINO, Calif., Feb. 24, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2016 financial results press release, you are invited to listen to a conference call ...
- Zacks Small Cap Research•10 days ago
By Grant Zeng, CFA NASDAQ:DRRX Among Durect’s (NASDAQ:DRRX) multiple candidates, DUR-928 may be the most promising one in our view because this compound has the potential to target multiple indications ...
- PR Newswire•26 days ago
CUPERTINO, Calif., Jan. 30, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today provided an update on the DUR-928 development program. DUR-928, our Epigenetic Regulator Program's lead product candidate, is an endogenous, small molecule, new chemical entity (NCE), which may have broad applicability in several metabolic diseases such as nonalcoholic steatohepatitis (NASH) and other liver conditions, and in acute organ injuries such as acute kidney injury (AKI). An abstract for this study has been accepted and data from the study will be presented at the International Liver Congress™ 2017 organized by the European Association for the Study of the Liver (EASL) in Amsterdam, April 19-23, 2017.
DRRX : Summary for DURECT Corporation - Yahoo Finance
DURECT Corporation (DRRX)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Ask||1.06 x 5500|
|Day's Range||0.97 - 0.98|
|52 Week Range||0.96 - 2.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.90|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|